Today's downgrade by Buckingham based on AGN's valuation is a great time for those seeking an entry point.
The FDA's recent approval of AGN's "Cohesive Gel Mammary Implants" for the U.S. Market should give a boost to Allergan's leadership is this sector and should add to sales.
The reason for the downgrade is a bit specious; however, when you are handed a lemons why not make some tasty lemonade.
I always add to my position when the "AGN-Bull" takes a breather. This tactic has served me well since last summer, and it should serve the "aggressive cognoscente investor", especially after the flurry of adroit and strategic Mgmt activity of the past 4 months..